Perspective Therapeutics (CATX) Company Report

Perspective Therapeutics (CATX) is advancing three clinical programs in radiopharmaceuticals: VMT-α-NET for neuroendocrine tumors, a melanoma program, and PSV359 for advanced solid tumors.
The VMT-α-NET program has demonstrated promising initial Phase 1 data, including a 39% overall response rate and 78% progression-free survival with over one year follow-up, alongside a compelling safety profile. The FDA has granted fast-track designation and encouraged its development as a front-line therapy alternative.
The company has secured end-to-end manufacturing and is building a network of facilities across the US (New Jersey, Iowa, Chicago, Houston, LA) to support commercial scalability and ensure a reliable supply chain for its short-shelf-life therapies.
Perspective Therapeutics reported $174 million in cash from its last quarterly filing, which is projected to last until the end of the year. Data updates for the VMT-α-NET and melanoma programs are expected in mid-2026, with FAP-alpha program updates later in the year.

Jan 14, 2026, 10:15 PM

Transcript

Perspective Therapeutics provides clinical and manufacturing updates at J.P. Morgan Healthcare Conference

CATX

New Projects/Investments

Guidance Update

Perspective Therapeutics (CATX) is advancing three clinical programs, including VMT-α-NET for neuroendocrine tumors, a melanoma program, and PSV359 for advanced solid tumors.
The VMT-α-NET program has received fast-track designation and shown promising initial Phase 1 data, including a 39-44% overall response rate and 78-81% progression-free survival, with a favorable safety profile, leading to consideration for a registrational trial.
The company's proprietary platform utilizes the lead-212 isotope for targeted alpha therapy and its imaging twin, lead-203, for patient selection, designed to optimize biodistribution and reduce off-target toxicity.
Perspective Therapeutics has secured end-to-end manufacturing capabilities and is expanding a network of facilities to support commercial scalability and ensure timely delivery of its radiopharmaceutical therapies.
The company anticipates providing more data updates across its clinical programs throughout 2026 and the current year.

Jan 14, 2026, 10:15 PM

Transcript

Perspective Therapeutics (CATX) discusses radiopharmaceutical pipeline and manufacturing capabilities

CATX

New Projects/Investments

Guidance Update

Perspective Therapeutics (CATX) is advancing its radiopharmaceutical pipeline, leveraging a proprietary chemical chelator and Lead-212 alpha emitter for targeted cancer treatment, with Lead-203 used for patient selection and imaging.
The company has three clinical programs: VMT-α-NET for neuroendocrine tumors, a melanoma program targeting MC1R, and a PSV359 program for advanced solid tumors targeting FAP-alpha. The VMT-α-NET program has demonstrated a compelling safety profile with no DLTs or discontinuations due to adverse events.
Perspective Therapeutics has established end-to-end manufacturing capabilities, including the ability to stockpile the parent isotope Thorium-228, which supports a scalable supply chain for its radiopharmaceuticals.
The company reported a strong financial position with $174 million in cash from its last quarterly filing, expected to fund operations until the end of the year.
Upcoming data catalysts include mid-2026 updates for the VMT-α-NET and melanoma programs, with updates for the FAP-alpha program expected later in the year.

Jan 14, 2026, 10:15 PM

Transcript

Perspective Therapeutics Announces Business Updates and Strategic Priorities

CATX

New Projects/Investments

Guidance Update

Perspective Therapeutics, Inc. announced business updates and strategic priorities, including a presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
For its lead program, VMT-α-NET, updated interim data as of December 10, 2025, showed it was well-tolerated in 56 patients and demonstrated durable disease control and deepening of tumor response in neuroendocrine tumors, with 76% (19 of 25 patients) without progression and remaining alive.
The company expects clinical updates in mid to late 2026 for VMT01 (melanoma) and PSV359 (FAP across solid tumors), and is expanding its manufacturing capabilities to support future growth.

Jan 12, 2026, 1:20 PM

8-K

Perspective Therapeutics Provides Updates on Radiopharmaceutical Pipeline and Financial Outlook

CATX

New Projects/Investments

Guidance Update

Perspective Therapeutics' lead program, VMT-α-NET, for SSTR2 positive tumors, demonstrated a 44% overall response rate (ORR) in GAP-NET patients compared to Lutathera's 13% ORR, with a stronger safety profile. Additional data from higher dose cohorts is expected next year.
The company is also advancing VMED 01, 02 for metastatic melanoma (targeting MC1R) and a FAP-targeting program for solid tumors, with data from both expected next year.
Perspective Therapeutics has a cash balance of $172 million on its balance sheet, with a historical quarterly burn of approximately $20 million, extending its cash runway until the end of 2026.
The company is expanding its manufacturing capabilities with operational sites in Iowa and New Jersey, and new facilities under development in Chicago, Houston, and Los Angeles, alongside a secured strategic thorium stockpile for several years.

Dec 2, 2025, 6:00 PM

Transcript

Perspective Therapeutics (CATX) Provides Update on Clinical Programs, Financials, and Manufacturing

CATX

New Projects/Investments

Guidance Update

Perspective Therapeutics (CATX) reported a cash runway extending until the end of 2026, with $172 million on its balance sheet from its last filing and a historical burn rate of approximately $20 million per quarter.
The company's lead program, VMT-α-NET, for SSTR2 positive neuroendocrine tumors, demonstrated a 44% Overall Response Rate (ORR) in GAP-NETs, compared to Lutathera's 13% ORR, with an "incredibly safe" profile showing no long-term renal toxicity or dysphagia. The company is discussing a registrational trial with the FDA, with the 5 mCi dose considered suitable.
Perspective Therapeutics is also advancing its VMED 01, 02 program for MC1R-positive metastatic melanoma and a FAP program for solid tumors, with data from both programs expected next year.
The company has operational manufacturing sites in Iowa and New Jersey, and is developing additional facilities in Chicago, Houston, and L.A. to scale up production and handle various isotopes.

Dec 2, 2025, 6:00 PM

Transcript

Perspective Therapeutics Discusses Radiopharmaceutical Pipeline and Financial Outlook

CATX

New Projects/Investments

Guidance Update

Perspective Therapeutics highlighted its VMT-α-NET program, an alpha-emitter radiopharmaceutical for SSTR2 positive neuroendocrine tumors, reporting a 44% overall response rate (ORR) in a like-for-like comparison at ESMO, significantly higher than Lutathera's 13% ORR, with a favorable safety profile.
The company is developing other radiopharmaceutical programs, including VMED 01, 02 for metastatic melanoma (targeting MC1R) and a FAP program for solid tumors, with data expected next year for both.
Perspective Therapeutics reported a cash runway extending until the end of 2026, with $172 million on the balance sheet and a historical burn rate of approximately $20 million per quarter.
The company is expanding its manufacturing capabilities with operational sites in Iowa and New Jersey, and new facilities under development in Chicago, Houston, and Los Angeles, supported by a strategic thorium stockpile.

Dec 2, 2025, 6:00 PM

Transcript

Perspective Therapeutics, Inc. Announces Q3 2025 Results and Business Highlights

CATX

Earnings

New Projects/Investments

Guidance Update

Perspective Therapeutics, Inc. reported a net loss of $26.0 million, or $0.35 per basic and diluted share, for the three months ended September 30, 2025.
As of September 30, 2025, the company held approximately $174 million in cash, cash equivalents, and short-term investments, which is expected to fund current planned clinical milestones and operational investments into late 2026.
The company provided an update on its [212Pb]VMT-α-NET Phase 1/2a study, noting that eight patients have been enrolled into Cohort 3 (6.0 mCi) within three months of its opening.

Nov 10, 2025, 9:20 PM

8-K

Perspective Therapeutics discusses updated VMT-α-NET clinical data at ESMO 2025

CATX

New Projects/Investments

Guidance Update

Perspective Therapeutics presented updated interim clinical data for its VMT-α-NET program at the European Society for Medical Oncology Congress 2025 (ESMO), reporting an objective response rate (ORR) of 44% in patients where all tumors expressed SSTR2, with a median follow-up of 41 weeks.
The 5 millicuries dose cohort of the VMT-α-NET program demonstrated a compelling clinical profile with strong anti-tumor activity and a favorable safety profile, including no dose-limiting toxicities, no grade 4 or 5 adverse events, and no treatment-related discontinuations.
Recruitment has been completed for the 5 millicuries dose cohort and has begun for the 6 millicuries DLT cohort in the VMT-α-NET program.
The company anticipates providing additional anti-tumor activity data from nearly all cohorts by early 2026, with further longer-term data and results from the 6 millicuries dose cohort expected by mid-2026.

Oct 20, 2025, 12:30 PM

Transcript

CATX Provides Positive Clinical Update for VMT-α-NET and Financial Outlook

CATX

New Projects/Investments

Guidance Update

CATX's VMT-α-NET, a targeted alpha-particle therapy for advanced SSTR2+ neuroendocrine tumors (NETs), demonstrated an Objective Response Rate (ORR) of 44% (7 of 16 patients with SSTR2+ tumors) at a median follow-up of 41 weeks in its Phase 1/2 study.
The treatment was well-tolerated, with no grade 4 or 5 adverse events or treatment-related discontinuations reported among the 55 patients treated as of September 12, 2025.
This interim data suggests potential for greater efficacy compared to Lutathera (13% ORR) and supports a potential registration study.
As of September 30, 2025, CATX reported ~$174 million in cash, cash equivalents, and short-term investments, providing sufficient funding into late 2026.
Upcoming data milestones for VMT-α-NET include anti-tumor activity data from nearly all Cohort 2 patients in early 2026 and initial anti-tumor activity data from the first 8 Cohort 3 patients in mid-2026.